Mavacamten in obstructive hypertrophic cardiomyopathy: a profile of its use
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical)
Link
https://link.springer.com/content/pdf/10.1007/s40267-023-01003-2.pdf
Reference38 articles.
1. Kawana M, Spudich JA, Ruppel KM. Hypertrophic cardiomyopathy: mutations to mechanisms to therapies. Front Physiol. 2022;13:975076.
2. Suay-Corredera C, Alegre-Cebollada J. The mechanics of the heart: zooming in on hypertrophic cardiomyopathy and cMyBP-C. FEBS Lett. 2022;596(6):703–46.
3. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2020;76(25):e159-240.
4. Larkin HD. Targeting the cause of obstructive hypertrophic cardiomyopathy. JAMA. 2022;327(21):2067.
5. Taddei-Allen P. Considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy. J Manag Care Spec Pharm. 2022;28(3):376–8.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3